Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...
Business Wire1mon
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a ...
Hosted on MSN22h
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and ...
Dallas Innovates5d
Alpha Cognition Inks $44M Licensing Agreement With China’s CMS for Alpha’s ZUNVEYL Alzheimer’s Drug
The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...
Hosted on MSN1mon
Alpha Cognition to delist from Canadian Securities Exchange
Alpha Cognition (NASDAQ:ACOG) said that it will voluntarily delist its common shares from the Canadian Securities Exchange.The shares will be delisted from the Canadian Securities Exchange at the ...
Business Wire1mon
Alpha Cognition Announces Voluntary Delisting from CSE
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection ...
Nasdaq1mon
Alpha Cognition Reports Promising Data for Brain Injury Drug
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Alpha Cognition Inc. has released promising interim preclinical data for its drug ALPHA-1062, aimed at treating ...
CNN2mon
Alpha Cognition Inc
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.
The Globe and Mail1mon
Alpha Cognition Announces Voluntary Delisting from CSE
Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will ...